Effects of the Antifungal Agent Itraconazole on Proliferative Changes of the Forestomach Mucosa in Alloxan-induced Diabetic Rats

被引:9
作者
Sano, Tomoya [1 ]
Ozaki, Kiyokazu [1 ]
Kodama, Yasushi [2 ]
Matsuura, Tetsuro [1 ]
Narama, Isao [1 ]
机构
[1] Setsunan Univ, Dept Pathol, Fac Pharmaceut Sci, Osaka, Japan
[2] Hiroshima Int Univ, Fac Pharmaceut Sci, Lab Mol & Cellular Toxicol, Hiroshima, Japan
关键词
antifungal agent; C; albicans; COX-2; itraconazole; squamous cell carcinoma; CANDIDA-ALBICANS; CARCINOGENESIS; TUMORS; MICE;
D O I
10.1177/0192623309344204
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Alloxan-induced diabetic rats frequently exhibit proliferative lesions of squamous hyperplasia accompanied by chronic inflammation and Candida albicans infection in the forestomach, and some lesions progress to squamous cell carcinoma (SCC). Candida infection causes not only hyperplastic changes with inflammation but might also lead to SCC in human oral mucosa. Thus, the present study was conducted to examine the effects of the antifungal agent itraconazole (ITCZ) on proliferative and inflammatory changes of the forestomach in alloxan-induced diabetic WBN/Kob rats. Diabetes was induced by alloxan at fifteen weeks of age. Rats were allocated to three groups at forty-five weeks of age and were given ITCZ by gavage 0 (vehicle control), 5, and 10 mg/kg/day for four weeks, and they were sacrificed at the sixty-fifth week of age. Mucosal hyperplastic changes were consistently accompanied by inflammation and Candida infections in the 0 mg/kg group. These lesions were reduced by ITCZ (0 mg/kg; 100%, 5 mg/kg; 53.5%, 10 mg/kg; 61.5%). Squamous cell carcinoma was detected in three rats from the 0 mg/kg, but only one rat from the 10 mg/kg dose groups in this study. Itraconazole reduced the degree of mucosal hyperplasia, inflammatory changes, and Candida infection. Therefore, C. albicans infection was an important factor in pathogenesis of mucosal proliferation and inflammation.
引用
收藏
页码:790 / 798
页数:9
相关论文
共 27 条
  • [1] [Anonymous], 2005, JOSLINS DIABETES MEL
  • [2] Barrett A W, 1998, Oral Dis, V4, P26
  • [3] TREATMENT OF ORAL CANDIDOSIS WITH ITRACONAZOLE - A REVIEW
    BLATCHFORD, NR
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 23 (03) : 565 - 567
  • [4] DAVID KM, 2009, TOXICOL PATHOL, V37, P249
  • [5] Comparison of itraconazole and ketoconazole in HIV-positive patients with oropharyngeal or esophageal candidiasis
    deRepentigny, L
    Ratelle, J
    Baril, JG
    Frechette, G
    MontCarmel, C
    Tsoukas, C
    Lemieux, C
    Vincelette, J
    Lalonde, R
    Rene, P
    Phaneuf, D
    Cote, P
    Dascal, A
    Auger, P
    Cholette, P
    StGermain, G
    [J]. CHEMOTHERAPY, 1996, 42 (05) : 374 - 383
  • [6] Candida albicans induces selectively transcriptional activation of cyclooxygenase-2 in HeLa cells:: Pivotal roles of toll-like receptors, p38 mitogen-activated protein kinase, and NF-κB
    Deva, R
    Shankaranarayanan, P
    Ciccoli, R
    Nigam, S
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (06) : 3047 - 3055
  • [7] DOUROV N, 1987, MYKOSEN, V30, P175
  • [8] *I LAB AN RES, 2000, ILAR J, V41
  • [9] Oral administration of itraconazole solution has superior efficacy in experimental oral and oesophageal candidiasis in mice than its intragastric administration
    Ishibashi, Hiroko
    Uchida, Katsuhisa
    Nishiyama, Yayoi
    Yamaguchi, Hideyo
    Abe, Shigeru
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (02) : 317 - 320
  • [10] Candida albicans phospholipomannan is sensed through toll-like receptors
    Jouault, T
    Ibata-Ombetta, S
    Takeuchi, O
    Trinel, PA
    Sacchetti, P
    Lefebvre, P
    Akira, S
    Poulain, D
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) : 165 - 172